These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1259 related articles for article (PubMed ID: 8473405)

  • 1. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
    J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
    Elahi D; McAloon-Dyke M; Fukagawa NK; Meneilly GS; Sclater AL; Minaker KL; Habener JF; Andersen DK
    Regul Pept; 1994 Apr; 51(1):63-74. PubMed ID: 8036284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects.
    Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
    Digestion; 1992; 52(3-4):214-21. PubMed ID: 1459356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas.
    Fehmann HC; Göke R; Göke B; Bächle R; Wagner B; Arnold R
    Biochim Biophys Acta; 1991 Feb; 1091(3):356-63. PubMed ID: 1705823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8.
    Fieseler P; Bridenbaugh S; Nustede R; Martell J; Orskov C; Holst JJ; Nauck MA
    Am J Physiol; 1995 May; 268(5 Pt 1):E949-55. PubMed ID: 7762650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia.
    Toft-Nielsen M; Madsbad S; Holst JJ
    Diabetologia; 1998 Oct; 41(10):1180-6. PubMed ID: 9794105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice.
    Pacini G; Thomaseth K; Ahrén B
    Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
    Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
    Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
    Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W
    J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.
    Nauck MA; Siemsglüss J; Orskov C; Holst JJ
    Z Gastroenterol; 1996 Mar; 34(3):159-66. PubMed ID: 8650968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
    Lund A; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
    Am J Physiol Endocrinol Metab; 2011 Jun; 300(6):E1038-46. PubMed ID: 21386059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
    Meier JJ; Kemmeries G; Holst JJ; Nauck MA
    Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8.
    Nauck M; Schmidt WE; Ebert R; Strietzel J; Cantor P; Hoffmann G; Creutzfeldt W
    J Clin Endocrinol Metab; 1989 Sep; 69(3):654-62. PubMed ID: 2668324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
    Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
    J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced insulinotropic effects of glucagonlike peptide I-(7-36)-amide and gastric inhibitory polypeptide in isolated perfused diabetic rat pancreas.
    Suzuki S; Kawai K; Ohashi S; Mukai H; Murayama Y; Yamashita K
    Diabetes; 1990 Nov; 39(11):1320-5. PubMed ID: 2146178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans.
    Meier JJ; Goetze O; Anstipp J; Hagemann D; Holst JJ; Schmidt WE; Gallwitz B; Nauck MA
    Am J Physiol Endocrinol Metab; 2004 Apr; 286(4):E621-5. PubMed ID: 14678954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
    Meier JJ; Nauck MA; Kranz D; Holst JJ; Deacon CF; Gaeckler D; Schmidt WE; Gallwitz B
    Diabetes; 2004 Mar; 53(3):654-62. PubMed ID: 14988249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.